{"id":"NCT02141204","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants","officialTitle":"Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-20","primaryCompletion":"2019-12-28","completion":"2019-12-28","firstPosted":"2014-05-19","resultsPosted":"2020-12-09","lastUpdate":"2020-12-09"},"enrollment":451,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Rotavirus"],"interventions":[{"type":"BIOLOGICAL","name":"HRV Liquid","otherNames":[]},{"type":"BIOLOGICAL","name":"HRV Lyophilized","otherNames":[]}],"arms":[{"label":"HRV Liq Group","type":"EXPERIMENTAL"},{"label":"HRV Lyo Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of GSK Biologicals' HRV liquid vaccine compared to GSK Biologicals' HRV lyophilized vaccine when administered as a two-dose primary vaccination in healthy infants aged 6-10 weeks at dose one, with no previous history of rotavirus illness or vaccination.\n\nWhile the lyophilized formulation of the HRV vaccine was licensed in India in February 2008, this study is conducted to generate additional clinical data for the liquid formulation of the HRV vaccine in India, as recommended by New Drug Advisory Committee on Vaccines (NDAC-Vaccines) of Drug Controller General of India (DCGI).","primaryOutcome":{"measure":"Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibody Concentrations","timeFrame":"At Month 2","effectByArm":[{"arm":"HRV Liq Group","deltaMin":90.25,"sd":null},{"arm":"HRV Lyo Group","deltaMin":94.16,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":22},"locations":{"siteCount":8,"countries":["India"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":224},"commonTop":["Irritability","Pyrexia","Decreased appetite","Cough","Vomiting"]}}